Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial

  • Regenxbio Inc RGNX announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME). 
  • The data were presented at the American Society of Retina Specialists Annual Meeting.
  • RGX-314 is a potential one-time gene therapy under development for wet age-related macular degeneration and DR.
  • Of the 15 patients dosed with RGX-314 in Cohort 1, five patients (33%) demonstrated a two-step or greater improvement from baseline on the disease severity scale at three months, compared to zero in the observational control group. 
  • One patient dosed with RGX-314 had a four-step improvement.
  • In the seven patients who had NPDR (DR severity level 47-53) at baseline, three patients (43%) demonstrated a two-step or greater improvement. 
  • In the eight patients who had PDR (DR severity level over 61) at baseline, two patients (25%) demonstrated a two-step or greater improvement.
  • Related: AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration.
  • Price Action: RGNX shares are up 1.07% at $32.01 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsgene therapyPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!